Ibogaine Treatment in the United States

American search interest in ibogaine treatment is larger than anywhere else, and the American answer is the most restrictive of any country covered on this site.

Why no clinician can offer it

Ibogaine is Schedule I, named in the text of the statute itself rather than added by an agency later. Schedule I means, in the law’s own terms, a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision.

The practical consequence is not the penalty. It is that there is no approved product, so there is nothing for a physician to prescribe and no lawful supply for a clinic to obtain. Why ibogaine is illegal covers how a 1970 statute produced that.

The three routes, and where each one stops

Schedule I research registration. The ordinary practitioner registration covers Schedules II to V only. Schedule I applications are referred to the health secretary, who assesses the practitioner’s qualifications and the merits of the research protocol. This is a research route by design and produces no treatment service.

Expanded access for an individual patient. The regulations permit the agency to allow an investigational drug to be used for the treatment of an individual patient by a licensed physician. The binding constraint is that it requires an existing investigational application or a sponsor’s authorisation letter, which means a manufacturer willing to supply.

Right to Try. This is the route the executive order names, and its conditions are cumulative. The drug must have completed a phase 1 trial; must not be approved; must be the subject of a filed application or under investigation in a trial that is the subject of an active investigational application; and its active development or production must be ongoing and not discontinued or on hold.

What the executive order did and did not do

Executive Order 14401, signed 18 April 2026, is the only presidential document in the Federal Register that mentions ibogaine. It directs the drug agencies to facilitate and establish a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under right-to-try legislation.

It reschedules nothing. Ibogaine remains Schedule I, and an instruction to build a pathway is an instruction.

Note also the number. A different order, 14396, circulates attached to this story; it concerns college football broadcasting. Joe Rogan on iboga covers how the story travelled.

The regulator’s own framing, six days later

On 24 April 2026 the medicines regulator announced it had allowed the first American clinical study of an ibogaine derivative, a phase 1 study of a noribogaine compound.

Its own qualification is the sentence to keep:

The FDA’s decision allows the study to proceed and does not mean the drug has been approved or found to be safe or effective.

A first phase 1 study of a derivative is a long way from a treatment, and it is the strongest signal available of where the American process actually stands. What the trials found sets the wider registry picture.

The prosecution

This is the part that rarely appears in coverage of the policy movement.

In January 2023 a man was indicted for distribution of ibogaine resulting in death. In September 2025 he was sentenced to 48 months. The department’s account records that he left the person unattended, returned to find them unresponsive, and that at the sentencing hearing the court found that the ibogaine he distributed caused the person’s death.

The prosecutor’s statement is unusually plain for a press release: ibogaine is dangerous, and taking it can have deadly consequences.

Two things follow. Providing ibogaine in the United States carries real criminal exposure, and the federal position on the substance is not merely administrative.

The states

Several states have moved, and none of them has created a treatment route.

Texas appropriated state matching funds for a clinical trial run by a public university in partnership with a drug company and a hospital. That is research money. Kentucky considered a proposal that did not proceed. Ibogaine in the United States maps the states, and Texas covers what that programme is.

A trial enrols a small number of people under a protocol. It is not a service you can buy, and it will not be one for years.

What people do instead

They travel, generally to Mexico, and finding treatment sets out what that means legally and what it costs in recourse.

Before that, the comparison worth making honestly: if this is for opioid dependence, the treatments with established mortality benefit are available in the United States now, and leaving them for an unproven one is a risk addiction physicians have published about specifically. After treatment covers why.